San Diego – September 28, 2015 – Ansun Biopharma announced today the publication of a report by researchers at the Centers for Disease Control demonstrating the strong inhibition of Enterovirus68 (EV68) by DAS181.
San Diego – July 27, 2015 – Ansun BioPharma, Inc., a San Diego-based biotech company, is pleased to announce that an investigation by the United States Attorney’s office over the misconduct of the former CEO and CFO has been dismissed.
San Diego – July 7th, 2015 – Ansun Biopharma announced today the publication of the report “Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181 (FluDaseTM), a host-directed antiviral” in the peer the reviewed Journal “Antiviral Research.”
San Diego – January 8, 2015 – Ansun Biopharma, Inc., a San Diego-based biotech company, is pleased to announce that it has entered into an agreement with the United States Attorneys Office resolving an investigation of Ansun.
San Diego – September 9, 2014 – Ansun BioPharma Announces Late Breaker Oral Presentation at ICAAC on the Clinical Activity of ParaDase™, an Investigational Drug for the Treatment of Severe Parainfluenza Infection.